The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2015
Filed:
Jun. 06, 2008
Jean-pierre André Marc Bongartz, Turnhout, BE;
Joannes Theodorus Maria Linders, Eindhoven, NL;
Lieven Meerpoel, Beerse, BE;
Guy Rosalia Eugeen Van Lommen, Berlaar, BE;
Erwin Coesemans, Nijlen, BE;
Mirielle Braeken, Wechelderzande, BE;
Christophe Francis Robert Nestor Buyck, Hamme, BE;
Monique Jenny Marie Berwaer, Manhay, BE;
Katharina Antonia Germania J. M. DE Waepenaert, Vosselaar, BE;
Peter Walter Maria Roevens, Malle, BE;
Gustaaf Maria Boeckx, Oud-Turnhout, BE;
Petr Vladimirivich Davidenko, Moscow, RU;
Jean-Pierre André Marc Bongartz, Turnhout, BE;
Joannes Theodorus Maria Linders, Eindhoven, NL;
Lieven Meerpoel, Beerse, BE;
Guy Rosalia Eugeen Van Lommen, Berlaar, BE;
Erwin Coesemans, Nijlen, BE;
Mirielle Braeken, Wechelderzande, BE;
Christophe Francis Robert Nestor Buyck, Hamme, BE;
Monique Jenny Marie Berwaer, Manhay, BE;
Katharina Antonia Germania J. M. De Waepenaert, Vosselaar, BE;
Peter Walter Maria Roevens, Malle, BE;
Gustaaf Maria Boeckx, Oud-Turnhout, BE;
Petr Vladimirivich Davidenko, Moscow, RU;
Janssen Pharmaceutica N.V., Beerse, BE;
Abstract
The invention relates to a DGAT inhibitor of formula (I): including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents —C(═O)—; —O—C(═O)—; C(═O)—C(═O)—; —NR—C(═O)—; —Z—C(O)—; —Z—NR—C(═O)—; —C(═O)—Z—; —NR—C(═O)—Z—; —S(═O)p-; —C(═S)—; —NR—C(═S)—; —Z—C(═S)—; —Z—NR—C(═S)—; —C(═S)—Z1-; —NR—C(═S)—Z—; Y represents NR—C(=0)-Z—; —NR—C(=0)-Z—NR—; —NR—C(=0)-Z—NR—C(=0)-; —NR—C(=0)-Z—NR—C(=0)-O—; —NR—C(=0)-Z-0-; —NR—C(=0)-Z-0-C(=0)-; —NR—C(=0)-Z—C(=0)-; —NR—C(=0)-Z—C(=0)-; —NR—C(=0)-0-Z—C(=0)-; —NR—C(=0)-0-Z—C(=0)-0-; —NR—C(═O)—O—Z—O—C(═O)—; —NR—C(═O)—Z—C(═O)—NR—; —NR—C(═O)—Z—NR—C(=0)-NR—; —C(═O)—Z—; —C(═O)—Z—O—; —C(=0)-NR—Z—; —C(=0)-NR—Z-0-; —C(=0)-NR—Z—C(=0)-0-; —C(=0)-NR—Z-0-C(=0)-; —C(=0)-NR—Z—NR—; —C(=0)-NR—Z—NR—C(=0)-; —C(=0)-NR—Z—NR—C(=0)-0-; Rrepresents Calkyl optionally substituted with cyano, Calkyloxy, Calkyl-oxyCalkyloxy, CCycloalkyl or aryl; Calkenyl; Calkynyl; Ccycloalkyl; adamantanyl; aryl; arylCalkyl; Het; or HetCalkyl; provided that when Y represents —NR—C(═O)—Z—; —NR—C(=0)-Z—NR; —NR—C(═O)—Z—C(═O)—NR—; —C(═O)—Z—; —NR—C(=0)-Z—NR—C(=0)-NR—; —C(═O)—NR—Z—; —C(═O)—NR—O—Z—; or —C(=0)-NR—Z—NR—; then Rmay also represent hydrogen; Rrepresents hydrogen, Calkyl, Calkenyl or R; provided that if X represents —O—C(═O)—; the Rrepresents R; and provided that (A) is excluded; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.